CytoDyn Inc. appointed finance chief Robert E. Hoffman as CEO effective Oct. 20, putting him in charge as the biotechnology company faces funding pressure and prepares to present new cancer trial data.
CytoDyn’s board selected Hoffman on Oct. 16, the company disclosed in a Form 8-K. He has been its chief financial officer since May 15, 2025, and will continue as principal accounting officer. Hoffman previously led Kintara Therapeutics as president and CEO. Dr. Jacob Lalezari, CytoDyn’s CEO since November 2023, is moving to a non-executive position as head of research and translational sciences.
The handover comes as CytoDyn seeks financing for further drug development. As of Aug. 31, 2026, it had about $16.4 million in cash and cash equivalents and $49.7 million in current liabilities. Its quarterly filing warned that its finances cast substantial doubt on its ability to continue operating. CytoDyn expects to finance future work mainly through equity and debt sales, which could dilute existing shareholders.
CytoDyn’s board compensation committee approved Hoffman’s pay changes, including an annual base salary of $525,000 for the fiscal year ending May 31, 2027. His bonus target rises from 40% to 50%. The committee also approved options to buy 2.5 million shares, subject to vesting. Lalezari’s compensation was unchanged under the agreement for his research role.
CytoDyn said the leadership transition is intended to support its oncology development, regulatory goals and search for potential partners. Its investigational antibody leronlimab targets CCR5 and is being studied with trifluridine/tipiracil and bevacizumab in the Phase 2 CLOVER trial for previously treated metastatic colorectal cancer.
The company’s Oct. 19 investor presentation described findings to date as preliminary and said data cleaning and verification were continuing. CytoDyn plans to present updated CLOVER data Oct. 25 at the European Society for Medical Oncology congress in Madrid.
